| Literature DB >> 35773629 |
Jinlu Tong1, Qi Feng2, Chenpeng Zhang3, Xitao Xu1, Zhihua Ran4.
Abstract
BACKGROUND: CT enterography (CTE) is used routinely for assessment of activity and severity in Crohn's disease (CD), but there are few CTE scoring systems. The aim of this study was to develop a quantitative CTE scoring system for ileocolonic Crohn's disease activity.Entities:
Keywords: CT enterography; Crohn's disease; Disease activity; Ileocolonic
Mesh:
Year: 2022 PMID: 35773629 PMCID: PMC9248101 DOI: 10.1186/s12876-022-02389-5
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 2.847
Fig. 1Flow chart of patient selection
Baseline characteristics of the 49 Crohn’s disease patients
| Male gender ( | 30 (61.2%) |
| Median age at the inclusion (years, range) | 27 (18–69) |
| Median disease duration (months, range) | 5 (1–145) |
| Previous intestinal resection ( | 3 (6.1%) |
| Disease location | |
| Ileal, n (%) | 6 (12.2%) |
| Ileocolonic, n (%) | 36 (73.5%) |
| Colonic, n (%) | 7 (14.3%) |
| Perianal involvement, n (%) | 32 (65.3%) |
| Concomitant therapies | |
| 5-ASA (n, %) | 31 (63.3%) |
| Steroids (n, %) | 27 (55.1%) |
| Immunosuppressives (n, %) | 31 (63.3%) |
| Anti-TNF antibodies, n (%) | 27 (55.1%) |
| Median CRP (mg/l, range) | 18.2 (0.16–113) |
| Harvey–Bradshaw index, median (IQR) | 5 (1–10) |
| Harvey–Bradshaw index > 4, n (%) | 26 (53.1%) |
| CDEIS, median (IQR) | 9.5 (0.3–25.5) |
CTE findings for each ileocolonic segments in the 49 included Crohn’s disease patients
| Distal ileum n = 39 | Ascending colon n = 46 | Transverse colon n = 48 | Descending colon n = 49 | Sigmoid colon n = 49 | Rectum n = 49 | |
|---|---|---|---|---|---|---|
| Ulceration | 20 | 13 | 21 | 19 | 15 | 5 |
| Polyp | 0 | 11 | 12 | 12 | 2 | 0 |
| Mural stratification | 30 | 24 | 31 | 24 | 12 | 8 |
| Submucosal fat deposition | 3 | 2 | 1 | 1 | 1 | 2 |
| Sacculation of antimesenteric wall | 3 | 1 | 2 | 1 | 0 | 0 |
| Strictures | 1 | 0 | 1 | 0 | 0 | 0 |
| Comb sign | 6 | 3 | 8 | 10 | 9 | 2 |
| Perienteric fat hypertrophy | 7 | 4 | 5 | 0 | 0 | 0 |
| Mesenteric fibrofatty proliferation | 11 | 15 | 14 | 15 | 7 | 3 |
| Mural hyperenhancement (HU) | 194.13 + 122.23 | 127.51 + 70.69 | 153.38 + 101.19 | 125.16 + 93.15 | 108.5 + 94.3 | 98.4 + 86.2 |
| Mural thickness (mm) | 4.57 + 2.51 | 4.22 + 3.27 | 4.08 + 2.75 | 3.68 + 2.37 | 2.92 + 1.87 | 2.54 + 1.82 |
Prevalence of qualitative CTE findings according to endoscopic severity of ileocolonic lesions
| Normal mucosa | Non-ulcerative lesions | Ulceration | Active disease at endoscopy (CDEIS ≥ 3) | |
|---|---|---|---|---|
| No(N = 280) | 98 | 61 | 121 | 174 |
| Mural stratification | 6 (6.1%) | 24 (39.3%) | 99 (81.8%) | 122 (70.1%) |
| Ulceration | 3 (3.1%) | 12 (19.7%) | 78 (64.5%) | 89 (51.1%) |
| Polyp | 2 (2.0%) | 13 (21.3%) | 22 (18.2%) | 35 (20.1%) |
| Submucosal fat deposition | 1 (1.0%) | 3 (4.9%) | 6 (5.0%) | 9 (5.2%) |
| Sacculation of antimesenteric wall | 0 | 3 (4.9%) | 4 (3.3%) | 7 (4.0%) |
| Perienteric fat hypertrophy | 1 (1.0%) | 3 (4.9%) | 12 (9.9%) | 15 (8.6%) |
| Perienteric fat stranding | 2 (2.0%) | 9 (14.8%) | 54 (44.6%) | 63 (36.2%) |
| Comb sign | 1 (1.0%) | 2 (3.3%) | 35 (28.9%) | 37 (21.3%) |
Fig. 2Changes in quantitative CTE parameters according to endoscopic severity of ileocolonic lesions. A mural thickness, B post-contrast loop attenuation, C pre-contrast loop attenuation, D relative attenuation. *p < 0.01, ** p < 0.001
Fig. 3Correlation between the Crohn’s Disease Endoscopic Index of Severity (CDEIS) and CTEIA on a per-segment (A) and on a per-patient basis (B)
Fig. 4Receiver operating characteristic (ROC) curves of a CTEIA to predict presence of an endoscopic lesion (A) and presence of ulcerative lesions (B) in Crohn’s disease
Fig. 5A 30-year-old woman with severe Crohn’s disease, A axial multidetector CT image of the transverse colon shows abnormal wall thickening, transmural enhancement (full arrow) and ulcer (white arrow) with CTEIA score 18; B view at ileocolonoscopy shows longitudinal ulcer in the same segment with CDEIS score 29